News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Ulrike Harjes: Promising response rates with Nivolumab in TNBC patients
Sep 21, 2024, 15:21

Ulrike Harjes: Promising response rates with Nivolumab in TNBC patients

Ulrike Harjes, Senior Editor at Nature Medicine, posted the following on X:

“Out now in Nature Medicine ESMO24! In BELLINI, patients with early-stage TNBC received neoadjuvant Nivolumab with or without Ipilimumab, leading to ctDNA clearance & promising clinical response rates, especially in preselected patients with high TIL levels.”

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Authors: Iris Nederlof, Olga I. Isaeva, Manon de Graaf, Robbert C. A. M. Gielen, Noor A. M. Bakker, Adrianne L. Rolfes, Hannah Garner, Bram Boeckx, Joleen J. H. Traets, Ingrid A. M. Mandjes, Michiel de Maaker, Thomas van Brussel, Maksim Chelushkin, Elisa Champanhet, Marta Lopez-Yurda, Koen van de Vijver, José G. van den Berg, Ingrid Hofland, Natasja Klioueva, Ritse M. Mann, Claudette E. Loo, Frederieke H. van Duijnhoven, Victoria Skinner, Sylvia Luykx, Emile Kerver, Ekaterina Kalashnikova, Marloes G. J. van Dongen, Gabe S. Sonke, Sabine C. Linn, Christian U. Blank, Karin E. de Visser, Roberto Salgado, Lodewyk F. A. Wessels, Caroline A. Drukker, Ton N. Schumacher, Hugo M. Horlings, Diether Lambrechts & Marleen Kok.

Ulrike Harjes: Promising response rates with Nivolumab in TNBC patients

Source: Ulrike Harjes/X

Adrianne L. Rolfes BELLINI Bram Boeckx cancer Caroline A. Drukker Christian U. Blank Claudette E. Loo clinical response ctDNA Diether Lambrechts & Marleen Kok Ekaterina Kalashnikova Elisa Champanhet Emile Kerver ESMO24 Frederieke H. van Duijnhoven Gabe S. Sonke Hannah Garner Hugo M. Horlings Ingrid A. M. Mandjes Ingrid Hofland ipilimumab Iris Nederlof Joleen J. H. Traets José G. van den Berg Karin E. de Visser Koen van de Vijver Lodewyk F.A. Wessels Maksim Chelushkin Manon de Graaf Marloes G. J. van Dongen Marta Lopez-Yurda Michiel de Maaker Natasja Klioueva Nature Medicine nivolumab Noor A. M. Bakker Olga I. Isaeva OncoDaily Oncology Ritse M. Mann Robbert C. A. M. Gielen Roberto Salgado Sabine C. Linn Sylvia Luykx Thomas van Brussel TIL TNBC Ton N. Schumacher Ulrike Harjes Victoria Skinner
Special Coverage
Science
May 9, 2025, 04:20
Valerie Yang: What started out as an academic collaboration is now available as a treatment option for soft tissue sarcoma patients
Cancer Types
May 9, 2025, 02:44
Medulloblastoma: Breakthroughs in Types, Symptoms, Diagnosis, Treatment, and 2025 Advances in Care
Blog
May 9, 2025, 01:36
Laura Bukavina: We walk to fuel research and hope
Blog
May 8, 2025, 18:13
Highlights from the NCCN Oncology Policy Summit 2025
Opinion
May 8, 2025, 18:12
Erman Akkus highlights new platinum derivatives Aurkine 16 and 18 for cancer treatment
Career
May 8, 2025, 18:06
Wafik S. El-Deiry congratulated Brooke Verschleiser on winning 2025 Llealyn B. Clapp Prize at the Brown University
Career
May 8, 2025, 18:00
E. John Wherry elected to National Academy of Sciences for cancer immunotherapy research
Opinion
May 8, 2025, 17:53
Rahul Banerjee on impact of CBER decision on cancer care
Career
May 8, 2025, 17:44
Thor Halfdanarson on 2025 Mayo Clinic Oncology Review course featuring ASCO highlights
Blog
May 8, 2025, 17:38
Kristiyana Kaneva: Does Starting a New Job Feel Like Going Through the Five Stages of Grief?
Celebrities
May 8, 2025, 17:36
Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football
Insight
May 8, 2025, 17:31
Stephen V Liu highlights SYS6010 ADC Data in EGFR-mutant NSCLC at AACR25